- Statement of Ownership (SC 13G)
27 Septembre 2010 - 10:10PM
Edgar (US Regulatory)
|
UNITED
STATES
|
|
|
SECURITIES
AND EXCHANGE COMMISSION
|
|
|
Washington,
D.C. 20549
|
|
|
|
|
SCHEDULE
13G
Under
the Securities Exchange Act of 1934
(Amendment No. )*
Trubion
Pharmaceuticals, Inc.
(Name of Issuer)
Common
Stock, par value $0.001 per share
(Title of Class of
Securities)
(CUSIP Number)
(Date of Event
Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
o
|
Rule 13d-1(b)
|
x
|
Rule 13d-1(c)
|
o
|
Rule 13d-1(d)
|
*The remainder of this cover page shall be filled out for a reporting persons
initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information
required in the remainder of this cover page shall not be deemed to be
filed for the purpose of Section 18 of the Securities Exchange Act of
1934 (Act) or otherwise subject to the liabilities of that section of the
Act, but shall be subject to all other provisions of the Act (however, see the
Notes).
13G
CUSIP No. 89778N102
|
|
|
|
|
1
|
Names of Reporting Persons
I.R.S. Identification Nos. of Above Persons (Entities Only)
Abbott Laboratories
|
|
|
2
|
Check the Appropriate Box
if a Member of a Group (See Instructions)
|
|
|
(a)
|
o
|
|
|
(b)
|
o
|
|
|
3
|
SEC Use Only
|
|
|
4
|
Citizenship or Place of
Organization
Illinois
|
|
|
|
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With
|
5
|
Sole Voting Power
2,243,649
|
|
6
|
Shared Voting Power
0
|
|
7
|
Sole Dispositive Power
2,243,649
|
|
8
|
Shared Dispositive Power
0
|
|
|
9
|
Aggregate Amount
Beneficially Owned by Each Reporting Person
2,243,649
|
|
|
10
|
Check if the Aggregate
Amount in Row (9) Excludes Certain Shares (See Instructions)
o
|
|
|
11
|
Percent of Class
Represented by Amount in Row (9)
10.99%
|
|
|
12
|
Type of Reporting Person
(See Instructions)
CO
|
|
|
|
|
|
|
|
|
2
Item 1.
|
|
(a)
|
Name of Issuer:
Trubion Pharmaceuticals, Inc.
|
|
(b)
|
Address of Issuers
Principal Executive Offices:
2401 Fourth Avenue, Suite 1050
Seattle, WA 98121
|
|
Item 2.
|
|
(a)
|
Name of Person Filing:
Abbott Laboratories
|
|
(b)
|
Address of Principal
Business Office, or if none, Residence:
100 Abbott Park Road
Abbott Park, Illinois
60064-6400
|
|
(c)
|
Citizenship:
Illinois
|
|
(d)
|
Title of Class of
Securities:
Common Stock, par value $0.001 per share
|
|
(e)
|
CUSIP Number:
89778N102
|
|
Item 3.
|
If this statement is filed pursuant
to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
|
|
(a)
|
o
|
Broker
or dealer registered under section 15 of the Act (15 U.S.C. 78o);
|
|
(b)
|
o
|
Bank
as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
|
|
(c)
|
o
|
Insurance company as
defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
|
|
(d)
|
o
|
Investment
company registered under section 8 of the Investment Company Act of 1940
(15 U.S.C. 80a-8);
|
|
(e)
|
o
|
An
investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
|
|
(f)
|
o
|
An
employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
|
|
(g)
|
o
|
A
parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
|
|
(h)
|
o
|
A
savings association as defined in Section 3(b) of the Federal
Deposit Insurance Act (12 U.S.C. 1813);
|
|
(i)
|
o
|
A
church plan that is excluded from the definition of an investment company
under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C.
80a-3); or
|
|
(j)
|
o
|
Group,
in accordance with Rule 13d-1(b)(1)(ii)(J).
|
3
Item 4.
|
Ownership.
|
|
(a)
|
Amount beneficially
owned:
2,243,649
shares
|
|
(b)
|
Percent of class:
10.99%
|
|
(c)
|
Number
of shares as to which the reporting person has:
|
|
|
(i)
|
Sole
power to direct the vote:
2,243,649
|
|
|
(ii)
|
Shared
power to vote or direct the vote:
0
|
|
|
(iii)
|
Sole
power to dispose or direct the disposition of:
2,243,649
|
|
|
(iv)
|
Shared
power to dispose or direct the disposition of:
0
|
|
Facet Biotech Corporation, a Delaware Corporation
(the Company), was acquired by Abbott Laboratories, an Illinois corporation
(Abbott), pursuant to a transaction that was completed on April 21,
2010 (the Acquisition). Following the Acquisition, the Companys name was
changed to Abbott Biotherapeutics Corp.
In connection with the integration of the Company into Abbott
following the Acquisition, on September 27, 2010, the Company
transferred beneficial ownership of all 2,243,649 shares of common stock, par
value $0.001 of Trubion Pharmaceuticals, Inc. previously acquired by the
Company as reported on Schedule 13G filed by the Company on September 9,
2009, to Abbott.
|
|
|
Item 5.
|
Ownership of Five Percent or Less
of a Class.
|
If this statement is
being filed to report the fact that as of the date hereof the reporting
person has ceased to be the beneficial owner of more than five percent of the
class of securities, check the following:
o
|
|
Item 6.
|
Ownership of More than Five Percent
on Behalf of Another Person.
|
|
Not applicable.
|
|
Item 7.
|
Identification and Classification
of the Subsidiary Which Acquired the Security Being Reported on By the Parent
Holding Company.
|
|
Not
applicable.
|
|
Item 8.
|
Identification and Classification
of Members of the Group.
|
|
Not
applicable.
|
|
Item 9.
|
Notice of Dissolution of Group.
|
|
Not
applicable.
|
|
Item 10.
|
Certifications.
|
By
signing below I certify that, to the best of my knowledge and belief, the
securities referred to above were not acquired and are not held for the purpose
of or with the effect of changing or influencing the control of the issuer of
the securities and were not acquired and are not held in connection with or as
a participant in any transaction having that purpose or effect.
4
SIGNATURE
After reasonable inquiry and to the best of my
knowledge and belief, I certify that the information set forth in this
statement is true, complete and correct.
Date: September 27,
2010
|
|
|
|
|
ABBOTT LABORATORIES
|
|
|
|
|
|
By:
|
/s/
Thomas C. Freyman
|
|
Name:
|
Thomas C. Freyman
|
|
Its:
|
Executive Vice President, Finance
and Chief Financial Officer
|
5
Trubion Pharmaceuticals (MM) (NASDAQ:TRBN)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Trubion Pharmaceuticals (MM) (NASDAQ:TRBN)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Trubion Pharmaceuticals (MM) (NASDAQ): 0 recent articles
Plus d'articles sur